- Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
- Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
- Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
- Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib
As of last trade
Pharming Group NV (PHGN:BER) traded at 1.14, -9.88% below its 52-week high of 1.27, set on Aug 26, 2022.
0.6635Jun 17 20221.27Aug 26 2022
Markit short selling activity
|Market cap||740.75m EUR|
|EPS (TTM)||0.0408 |
Data delayed at least 15 minutes, as of Dec 08 2022 07:00 GMT.